IP Group Plc announced on 20 July 2026 that it has rejected a £630 million takeover proposal from Railways Pension Trustee Company Limited. The unsolicited cash offer valued the FTSE 250-listed science investor at 78 pence per share. IP Group's board determined the bid substantially undervalued the company and its future prospects, advising shareholders to take no action. The stock closed at 71.2 pence on the prior trading day, giving the company a market capitalisation of approximately £575 million. The proposed premium was 9.5% over that closing price.
Context — [why this matters now]
The UK's publicly-listed intellectual property commercialisation sector has seen elevated activity. The last significant hostile approach occurred in August 2024 when Allied Minds agreed to a 65 pence per share buyout from its largest shareholder, representing a 120% premium to its undisturbed price. IP Group itself was the subject of bid speculation in late 2025 following a strategic review that failed to unlock shareholder value, with its shares trading 45% below their 2021 peak.
The current macro backdrop features a Bank of England base rate of 4.75%, creating pressure on growth-oriented investment companies. Long-duration assets like early-stage science ventures have faced valuation headwinds. This environment has made cash-rich pension funds, seeking direct access to private asset returns, aggressive acquirers of discounted listed investment vehicles.
The immediate catalyst for Railpen's move appears to be IP Group's upcoming milestone-heavy period. Several of its largest portfolio companies, including gene therapy firm Freeline Therapeutics and battery materials developer Ilika, are due to report pivotal clinical and commercial trial data in Q3 2026. Railpen's bid attempted to secure ownership before potential positive news flow could materially re-rate the stock.
Data — [what the numbers show]
The rejected offer of 78 pence per share represented a 31% discount to IP Group's last reported net asset value (NAV) of 113 pence per share as of 31 December 2025. The company's portfolio was valued at £1.23 billion at that date, with its top ten holdings comprising 68% of the total. Top holdings include Oxford Nanopore Technologies, valued at £287 million, and Hysata, an electrolyser company valued at £152 million.
A comparison of valuation metrics against UK peer Imperial Brands illustrates the sector discount.
| Metric | IP Group | Imperial Brands (Peer) |
|---|
| Price / NAV | 0.63x | 0.92x |
| YTD Share Price Return | -7.2% | +3.1% |
| 5-Year Annualised Volatility | 38% | 22% |
The bid valued IP Group's stake in Oxford Nanopore alone at approximately £210 million, a 27% discount to its market value. The FTSE All-Share Index is up 4.1% year-to-date, while the FTSE 250 is down 1.8%. The offer represented a 12-month forward P/E multiple of 18.2, below the sector average of 21.5 for listed investment trusts.
Analysis — [what it means for markets / sectors / tickers]
The rejection signals board confidence in imminent portfolio realisations, potentially benefiting other UK science investors. Shares in Syncona Limited and RTW Venture Fund rose 3.1% and 2.4% respectively on the news, as markets priced in a sector re-rating. Conversely, it pressures other pension funds pursuing similar 'take-private' strategies, potentially raising acquisition costs for targets like Pantheon International.
A key counter-argument is that IP Group's reported NAV may be optimistic. Its valuation methodology relies heavily on funding round comparables for private companies, which have been scarce in 2026. A 10% writedown in the private book would bring the bid closer to a 0.7x NAV multiple, a more standard sector discount. The lack of a competing bidder at this stage supports this cautious view.
Positioning data from the London Stock Exchange shows short interest in IP Group fell from 2.8% to 1.1% of issued share capital following the announcement. Flow analysis indicates buyers were predominantly UK long-only funds, while transatlantic hedge funds were net sellers, betting the bid will not be revised upwards materially. The options market implies a 60% probability the share price trades between 75p and 85p over the next month.
Outlook — [what to watch next]
The next formal deadline is 17 August 2026, the date by which Railpen must either announce a firm intention to make an offer under UK takeover rules or walk away. Markets will scrutinise IP Group's half-year results, scheduled for 5 September 2026, for an updated NAV and commentary on portfolio progress.
Key clinical catalysts will directly impact valuation. Freeline Therapeutics reports Phase 3 data for its FLT190 gene therapy in Fabry disease on 15 September 2026. Ilika is due to release commercial-scale testing results for its Goliath solid-state battery on 22 October 2026. Positive results could add over 15p per share to NAV estimates.
Technical levels to watch include immediate resistance at the 78p bid price. A sustained break above 80p would target the 90p level, last seen in Q1 2025. Support rests at the 50-day moving average of 69p. A close below 67p would invalidate the bullish bid anticipation scenario and suggest the market expects no revised offer.
Frequently Asked Questions
What does the IP Group takeover rejection mean for retail investors?
Retail shareholders should await the board's formal response document, expected within 14 days. The rejection implies directors believe waiting for portfolio milestones will deliver more value than the current cash offer. Investors must assess their own time horizon against the company's projected 2-3 year timeline for key asset monetisation. The bid rejection does not prevent a higher offer, but it removes immediate certainty of cash exit at 78p.
How does Railpen's bid compare to other pension fund acquisitions?
The 9.5% premium is low by historical standards. The average premium for UK take-private deals in the investment company sector over the last five years is 22%. For example, when the Pension Insurance Corporation acquired The PRS REIT in 2025, the final offer represented a 28% premium to the pre-bid price. Railpen's initial lowball offer is a common tactic to initiate negotiations, not a final proposal.
